LCZ696 (sacubitril valsartan) available to NHS through EAMS New heart failure medicine LCZ696 (sacubitril valsartan) is to be made available to the NHS under the Early Access to Medicines Scheme […]
Tag: LCZ696
Novartis Entresto approval by the FDA
Novartis Entresto approval by the FDA Novartis new heart failure medicine LCZ696, now called Novartis Entresto approved by the FDA to reduce risk of cardiovascular death and heart failure hospitalisation […]
Novartis rebound from Serelaxin setback
Novartis rebound from Serelaxin setback Novartis announced today that the Data Monitoring Committee (DMC) unanimously recommended early closure of the PARADIGM-HF study, indicating patients with chronic heart failure with reduced […]